18+ · Research Use Only · Not for Human Consumption
Tirzepatide · Phase 3 · Completed
SURMOUNT-1
In SURMOUNT-1, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes (n=2,539), mean body weight fell 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks, against 3.1% on placebo (treatment-regimen estimand; Jastreboff AM et al. N Engl J Med 2022;387:205-216).
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
Results
Side effects reported
In SURMOUNT-1, discontinuation because of adverse events was 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg, against 2.6% on placebo.
| Event | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Discontinuation for adverse events | 4.3% | 7.1% | 6.2% | 2.6% |
Design
Trial design and sources
- Compound
- Tirzepatide
- Phase
- 3
- Population
- Adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes
- Participants randomised
- 2,539
- Duration
- 72 weeks
- Primary endpoint
- Coprimary: percentage change in weight from baseline and weight reduction of 5% or more (week 72)
- Estimand
- treatment-regimen
- Read out
- 4 June 2022
Treatment-regimen estimand, as the NEJM abstract reports it. Lilly's release (28 April 2022) gave 22.5% on 15 mg under the efficacy estimand; that figure is in lib/trials/tirzepatide.ts for like-for-like comparison with the TRIUMPH releases.
Questions
SURMOUNT-1, answered
What did SURMOUNT-1 find?
In SURMOUNT-1, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes (n=2,539), mean body weight fell 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks, against 3.1% on placebo (treatment-regimen estimand; Jastreboff AM et al. N Engl J Med 2022;387:205-216).
What side effects were reported in SURMOUNT-1?
In SURMOUNT-1, discontinuation because of adverse events was 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg, against 2.6% on placebo.
Related